Skip to main content
Caplight Logo









SparingVision

SparingVision

Private
ParisHealthcare & Life Scienceshttps://sparingvision.com/

Last Round

Series B

Sep 14, 2022

Total Funding Raised

$130.49M

Company Overview

SparingVision is a biotechnology company developing genomic medicines and gene-agnostic therapies for inherited retinal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapymutation-agnosticinherited retinal diseasesophthalmologyretinitis pigmentosagenomic medicinebiotechclinical-stage biotechneurotrophic factorsrare diseasedrug developmentclinical trialsbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SparingVision Comparables

Compare SparingVision with similar companies based on industry and business-model similarity.

SparingVision comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nanoscope Therapeutics Inc.
86%
Coave Therapeutics
86%
Restore Vision Inc.
85%

SparingVision Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 14, 2022
Series AOct 21, 2020
GrantJul 9, 2019
GrantJul 12, 2017

Key People

Founding team and executive leadership

Stephane Boissel

President & CEO, Chairman & CEO, Chairman of the Board

Executive Team

Rajiv Gangurde

Chief Technology Officer

Executive Team

Anjeza Gjino

Interim Chief Financial Officer

Executive Team

Guillaume Hagege

Chief Operating Officer

Executive Team

SparingVision Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 9, 2025

    Kalliopi 'Kali' Stasi appointed as the new Chief Medical Officer.

  • May 19, 2025

    Presented PRODYGY data and research update at ASGCT 2025.

SparingVision Filings

Explore SEC and related filing metadata, where available.

SparingVision filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SparingVision's valuation, stock price, and market status.

Is SparingVision a public or private company?

SparingVision is a private company.

What is the current stock price of SparingVision?

SparingVision is a private company with no public stock price. No recent secondary market data is available.

How much is SparingVision worth (valuation)?

Valuation information for SparingVision is not publicly available.

Can I buy SparingVision stock?

SparingVision shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SparingVision's last funding round?

SparingVision's most recent funding round was Series B on September 14, 2022.

Who are the main investors in SparingVision?

Key investors in SparingVision include 4Bio Capital, UPMC Enterprises, Jeito.

Will SparingVision IPO soon?

No public IPO plans have been announced for SparingVision.

How can I track SparingVision secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SparingVision's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range34
Year Founded2016
Last FundingSep 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?